Tectonic Therapeutic (TECX) Competitors $18.03 +0.72 (+4.16%) Closing price 09/11/2025 04:00 PM EasternExtended Trading$17.45 -0.58 (-3.22%) As of 09:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TECX vs. XERS, ELVN, COLL, NTLA, ABCL, EVO, CVAC, CALT, PHVS, and RCUSShould you be buying Tectonic Therapeutic stock or one of its competitors? The main competitors of Tectonic Therapeutic include Xeris Biopharma (XERS), Enliven Therapeutics (ELVN), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), AbCellera Biologics (ABCL), Evotec (EVO), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Pharvaris (PHVS), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. Tectonic Therapeutic vs. Its Competitors Xeris Biopharma Enliven Therapeutics Collegium Pharmaceutical Intellia Therapeutics AbCellera Biologics Evotec CureVac Calliditas Therapeutics AB (publ) Pharvaris Arcus Biosciences Xeris Biopharma (NASDAQ:XERS) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings. Is XERS or TECX more profitable? Tectonic Therapeutic has a net margin of 0.00% compared to Xeris Biopharma's net margin of -13.01%. Xeris Biopharma's return on equity of 0.00% beat Tectonic Therapeutic's return on equity.Company Net Margins Return on Equity Return on Assets Xeris Biopharma-13.01% N/A -8.00% Tectonic Therapeutic N/A -30.13%-28.33% Which has more volatility and risk, XERS or TECX? Xeris Biopharma has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, Tectonic Therapeutic has a beta of 3.42, meaning that its share price is 242% more volatile than the S&P 500. Which has preferable valuation & earnings, XERS or TECX? Xeris Biopharma has higher revenue and earnings than Tectonic Therapeutic. Xeris Biopharma is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXeris Biopharma$203.07M6.11-$54.84M-$0.21-36.57Tectonic TherapeuticN/AN/A-$57.98M-$4.04-4.46 Does the media prefer XERS or TECX? In the previous week, Xeris Biopharma had 7 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 12 mentions for Xeris Biopharma and 5 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 1.27 beat Xeris Biopharma's score of 1.19 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 6 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in XERS or TECX? 42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 6.5% of Xeris Biopharma shares are owned by company insiders. Comparatively, 38.0% of Tectonic Therapeutic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts rate XERS or TECX? Xeris Biopharma presently has a consensus target price of $7.08, indicating a potential downside of 7.77%. Tectonic Therapeutic has a consensus target price of $80.29, indicating a potential upside of 345.29%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, analysts clearly believe Tectonic Therapeutic is more favorable than Xeris Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xeris Biopharma 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Tectonic Therapeutic 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 SummaryTectonic Therapeutic beats Xeris Biopharma on 10 of the 16 factors compared between the two stocks. Get Tectonic Therapeutic News Delivered to You Automatically Sign up to receive the latest news and ratings for TECX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TECX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TECX vs. The Competition Export to ExcelMetricTectonic TherapeuticMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$323.91M$3.15B$5.78B$10.07BDividend YieldN/A2.32%5.69%4.62%P/E Ratio-4.4621.6075.0426.20Price / SalesN/A297.80469.7391.86Price / CashN/A45.3337.0859.91Price / Book1.899.7112.236.28Net Income-$57.98M-$53.33M$3.29B$270.85M7 Day Performance7.32%1.04%1.53%3.58%1 Month Performance-17.60%9.93%7.86%6.67%1 Year Performance3.03%13.80%63.05%27.74% Tectonic Therapeutic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TECXTectonic Therapeutic3.2512 of 5 stars$18.03+4.2%$80.29+345.3%+3.0%$323.91MN/A-4.46120Positive NewsXERSXeris Biopharma3.0622 of 5 stars$7.89+0.7%$7.08-10.2%+168.5%$1.27B$203.07M-37.45290Positive NewsELVNEnliven Therapeutics3.0471 of 5 stars$20.90+3.1%$41.20+97.1%-13.7%$1.24BN/A-10.4650Positive NewsInsider TradeCOLLCollegium Pharmaceutical3.5233 of 5 stars$38.99+0.5%$42.33+8.6%+7.9%$1.23B$631.45M37.49210Positive NewsNTLAIntellia Therapeutics4.3436 of 5 stars$11.39+0.2%$29.05+155.2%-43.6%$1.23B$57.88M-2.43600Analyst RevisionABCLAbCellera Biologics2.4588 of 5 stars$4.07-2.8%$8.00+96.8%+71.4%$1.22B$28.83M-7.43500EVOEvotec1.7053 of 5 stars$3.42-2.4%$5.40+58.1%+1.5%$1.21B$862.40M0.004,827Gap UpCVACCureVac3.9426 of 5 stars$5.39+0.3%$6.83+26.9%+77.9%$1.21B$579.18M5.61880Short Interest ↑CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180News CoveragePHVSPharvaris2.5684 of 5 stars$22.57+4.2%$35.60+57.7%+12.0%$1.18BN/A-6.7230Positive NewsRCUSArcus Biosciences1.7623 of 5 stars$10.86+2.5%$21.14+94.7%-32.2%$1.16B$258M-3.43500Positive News Related Companies and Tools Related Companies Xeris Biopharma Competitors Enliven Therapeutics Competitors Collegium Pharmaceutical Competitors Intellia Therapeutics Competitors AbCellera Biologics Competitors Evotec Competitors CureVac Competitors Calliditas Therapeutics AB (publ) Competitors Pharvaris Competitors Arcus Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TECX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredUrgent: $3,452.50 a Month in Passive "AI Equity Checks"The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tectonic Therapeutic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tectonic Therapeutic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TECX Stock Alerts